MIRA1A

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a life sciences company focused on the development of MIRA1a, a synthetic THC analog. MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and chronic pain without impurities or the negative side effects associated with cannabis plant extracts. MIRA1a is classified as an unscheduled drug by the U.S. Drug Enforcement Administration (DEA)... MIRA Pharmaceuticals, Inc. (MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of new molecular synthetic cannabinoid analog for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Our target patient population is also typically experiencing chronic pain.

Also known as: MIRA Pharmaceuticals, MIRA Pharmaceuticals, Inc.

Primary location: Baltimore United States